Alcon Gross Profit 2019-2022 | ALC

Alcon annual/quarterly gross profit history and growth rate from 2019 to 2022. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
  • Alcon gross profit for the quarter ending September 30, 2022 was $1.166B, a 2.43% decline year-over-year.
  • Alcon gross profit for the twelve months ending September 30, 2022 was $4.784B, a 10.72% increase year-over-year.
  • Alcon annual gross profit for 2021 was $4.652B, a 58.23% increase from 2020.
  • Alcon annual gross profit for 2020 was $2.94B, a 19.72% decline from 2019.
  • Alcon annual gross profit for 2019 was $3.662B, a 14.72% increase from 2018.
Alcon Annual Gross Profit
(Millions of US $)
2021 $4,652
2020 $2,940
2019 $3,662
2018 $3,192
Alcon Quarterly Gross Profit
(Millions of US $)
2022-09-30 $1,166
2022-06-30 $1,204
2022-03-31 $1,208
2021-12-31 $1,206
2021-09-30 $1,195
2021-06-30 $1,220
2021-03-31 $1,031
2020-12-31 $875
2020-09-30 $848
2020-06-30 $345
2020-03-31 $872
2019-12-31 $913
2019-09-30 $950
2019-06-30 $947
2019-03-31 $852
2018-12-31
2018-09-30 $568
2018-06-30 $878
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $37.369B $8.291B
Alcon Inc. researches, develops, manufactures, distributes, and sells a full suite of eye care products. Alcon operates within two segments, Surgical and Vision Care. The Surgical segment is focused on ophthalmic products for cataract surgery, vitreoretinal surgery, refractive laser surgery and glaucoma surgery, and includes implantables, consumables, and surgical equipment required for these procedures. The Vision Care segment comprises daily disposable, reusable and color-enhancing contact lenses, and a comprehensive portfolio of ocular health products, including products for dry eye, contact lens care, and ocular allergies, as well as ocular vitamins and redness relievers.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $230.517B 25.29
Edwards Lifesciences (EW) United States $50.772B 33.11
STERIS (STE) Ireland $21.864B 27.21
Teleflex (TFX) United States $12.124B 19.67
Fresenius Medical Care AG KGaA (FMS) Germany $11.123B 11.16
Penumbra (PEN) United States $9.913B 2372.91
Globus Medical (GMED) United States $7.951B 40.42
Glaukos (GKOS) United States $2.458B 0.00
Integer Holdings (ITGR) United States $2.435B 19.55
AVANOS MEDICAL, INC (AVNS) United States $1.469B 20.92
Nevro (NVRO) United States $1.410B 0.00
Paragon 28 (FNA) United States $1.346B 0.00
Artivion (AORT) United States $0.566B 0.00